Powys Shared Care Agreement: December 2014Shared Care Agreement • March 25th, 2022
Contract Type FiledMarch 25th, 2022🟋PLEASE CHECK ( POWYS FORMULARY WEBSITE ADDRESS)FOR THE LATEST VERSION OF THIS PROTOCOL🟋 General guidance This agreement outlines shared care arrangements for patients taking dexamfetamine or lisdexamfetamine dimesylate (lisdexamfetamine) for the treatment of Attention Deficit / Hyperactivity Disorder (ADHD).This Protocol does NOT cover the use of:1. lisdexamfetamine at doses above the maximum recommended in ADHD.2. Dexamfetamine at doses above the maximum recommended in ADHD. This Protocol should be read in conjunction with:⮚ The Shared Care Agreement Form (see below).⮚ NICE CG72 (September 2008, last modified March 2013 http://www.nice.org.uk/Guidance/CG72). Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. Note: NICE CG72 incorporates recommendations from NICE TA98 and TA102.⮚ The Summary of Product Characteristics (Data Sheet) for Elvanse® see: http://www.medicines.org.uk/ 1. Licensedindication Dexamfetamine and lisde